Claims for Patent: 4,356,170

Summary for Patent: 4,356,170

Title:	Immunogenic polysaccharide-protein conjugates
Abstract:	Antigenic polysaccharides are modified to generate a terminally-located aldehyde group by controlled oxidation of vicinal hydroxyl groups, e.g. of unlinked terminal non-reducing sialic acid residues. In some cases where there is a reducing end group, e.g. of the type N-acetylmannosamine residue, it can be made into the most susceptible site for oxidation by initially reducing it to its open chain hydroxyl form, e.g. N-acetylmannosaminitol. The vicinal hydroxyl oxidation is controlled to yield a reactive aldehyde group which is then covalently linked to a free amino group of a selected protein by reductive amination. The resulting polysaccharide-protein conjugates are soluble and have been found to have enhanced antigenicity compared to the polysaccharide alone. This terminal aldehyde:free amine group reductive amination can be applied to various polysaccharide antigens and various well-tolerated proteins, preferably protein immunogens. For example, meningococcal group A, B and C polysaccharides have been linked to tetanus toxoid to give soluble conjugates which have been found to have advantageous immunogenic properties.
Inventor(s):	Harold J. Jennings, Czeslaw Lugowski
Assignee:	National Research Council of Canada
Application Number:	US06/267,440

Details for Patent 4,356,170

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Biologicals	MENHIBRIX	meningococcal groups c and y and haemophilus b tetanus toxoid conjugate vaccine	Injection	125363	June 14, 2012	4,356,170	2001-05-27